Improving Hepatitis C Treatment in Injection Drug Users

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Steven Batki, M.D., State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT00148031
First received: September 2, 2005
Last updated: April 23, 2013
Last verified: April 2013
  Purpose

The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.

Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.


Condition Intervention Phase
Hepatitis C
Liver Diseases
Drug Abuse
Alcoholism
Drug: Pegylated Interferon and Ribavirin
Behavioral: Psychosocial
Behavioral: On-site (MMT Clinic) HCV evaluation and treatment
Behavioral: Off-site HCV evaluation and treatment
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Improving Hepatitis C Treatment in Injection Drug Users

Resource links provided by NLM:


Further study details as provided by State University of New York - Upstate Medical University:

Primary Outcome Measures:
  • Efficacy of On-site versus Off-site delivery of HCV medical care for methadone maintenance treatment (MMT) patients, as evaluated by the proportion of patients achieving sustained virological response (SVR). [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • psychiatric diagnoses and symptom severity [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 111
Study Start Date: September 2003
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
On-site (MMT Clinic) HCV evaluation and treatment
Drug: Pegylated Interferon and Ribavirin
Both groups with receive the same medical intervention but offered at different locations
Behavioral: Psychosocial
Assessment of the likelihood of HCV treatment initiation and completion
Behavioral: On-site (MMT Clinic) HCV evaluation and treatment
Standard HCV treatment with Pegylated Interferon and Ribavirin
Active Comparator: 2
Off-site (GI Clinic) HCV evaluation and treatment
Drug: Pegylated Interferon and Ribavirin
Both groups with receive the same medical intervention but offered at different locations
Behavioral: Psychosocial
Assessment of the likelihood of HCV treatment initiation and completion
Behavioral: Off-site HCV evaluation and treatment
Standard HCV treatment with Pegylated Interferon and Ribavirin

Detailed Description:

The overall goal of the proposed health services research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. This will be done by testing an intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs. This intervention will increase access by integrating HCV medical care into a substance abuse treatment program. HCV infection is endemic among IDUs, and is associated with significant medical morbidity. While antiviral treatments are improving rapidly, providing HCV medical care for IDUs remains problematic for a number of reasons. IDUs often do not have adequate access to HCV diagnosis and treatment services, and they may have co-morbid psychiatric diagnoses that affect the ability to withstand the demands of HCV treatment. Therefore, this study will also examine psychiatric disorders and psychiatric symptoms in IDUs who are infected with Hepatitis C virus.

The proposed project is a five-year program consisting of a controlled clinical trial, studying 220 patients with HCV infection enrolled in methadone maintenance treatment (MMT). The HCV Medical Care Study is a randomized trial to test the efficacy of On-site HCV Medical Care provided at the MMT program versus Off-site care at the Gastroenterology (GI) Clinic. HCV antibody positive MMT patients (N=220) will be randomly assigned to receive HCV medical services either through an integrated delivery model located on-site in the MMT clinic, or through usual off-site referral to the GI Clinic. The main outcomes will be the rates of attaining SVR and completion of HCV treatment, as well as other measures of HCV-related health outcomes and quality of life. Participants will be evaluated for Axis I psychiatric diagnoses and will complete psychiatric measures at monthly intervals throughout the study. Psychiatric diagnosis will be made using the Structured Psychiatric Interview for the DSM-IV (SCID) and psychiatric symptom severity will be assessed for depression, mania, anxiety, and psychosis. Drug use measures, and quality of life measures will also be obtained. These data are expected to yield new knowledge about the efficacy of providing on-site HVC medical care in substance abuse treatment programs. They will provide a comparison of psychiatric diagnoses and psychiatric symptom presentation in HCV positive IDUs who choose to receive HCV treatment and those who do not choose to follow through with HCV treatment and will describe changes in psychiatric symptoms before, during, and after HCV medical care. Finally, the studies will also provide information about the influence of psychiatric symptoms and drug and alcohol use on HCV medical outcomes such as treatment completion and SVR.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-65 years of age.
  2. Enrolled in outpatient methadone maintenance treatment for greater than 3 months.
  3. Hepatitis C RNA positive.
  4. Willingness to accept HCV treatment.
  5. Subject has non-VA (Veteran's Administration) medical insurance or is willing to bear any and all expenses associated with Hepatitis C medical treatment.

Exclusion Criteria:

  1. In need of inpatient drug or alcohol detoxification.
  2. Currently receiving the standard Hepatitis C treatment
  3. Unable to give adequate informed consent.
  4. Pregnant, nursing, or planning to become pregnant during HCV treatment or within 6 months following completion of treatment.
  5. Male subject who has a female sexual partner who is pregnant or planning to become pregnant at any time during HCV treatment or within 6 months following completion of treatment.
  6. Female subject or male subject who has a female sexual partner who is of child bearing years and not using two medically approved forms of contraception.
  7. Subject has made a commitment to attend residential care psychiatric or drug/alcohol rehabilitation, which would lead to unavailability to attend regularly scheduled medical care and research visits.
  8. Subject did not attend all required screening appointments.
  9. Subject has a legal proceeding whose outcome may lead to incarceration within 3 months of intake.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00148031

Locations
United States, New York
Crouse Chemical Dependency Treatment Services
Syracuse, New York, United States, 13210
SUNY Upstate Medical University - Department of Gastroenterology
Syracuse, New York, United States, 13210
Sponsors and Collaborators
State University of New York - Upstate Medical University
Investigators
Principal Investigator: Steven L Batki, MD State University of New York, Upstate Medical University - Department of Psychiatry
  More Information

Additional Information:
Publications:
Batki, S.L., Canfield, K.M., Cole, C., Smyth, E., Pham, H., Ploutz-Snyder, R.; Amodio, K., Manser, K., Knoeller, G., Strutynski, K., Levine, R., Dimmock J.A. (2007) (abstract) Psychiatric diagnosis and psychiatric symptom severity in methadone treatment patients with untreated hepatitis C virus infection. American Journal on Addictions, 16:316-17.
Batki, S.L., Canfield, K., Lundell, S., Levine, R., Donohue, L., Amodio, K. (oral presentation) Characteristics of opioid-dependent patients seeking Hepatitis C treatment. College on the Problems of Drug Dependence, Orlando, June.
Batki, S.L., Canfield, K.M., Cole, C., Ploutz-Snyder, R., Dimmock, J., Pham, H., Smythe, E. (oral presentation) Quality of life in MMT patients with untreated HCV infection. College on the Problems of Drug Dependence, Scottsdale, June 2006.
Batki, S.L.; Canfield, K.; Cole, C.; Smyth, E.; Ploutz-Snyder, R.; Levine, R.; Amodio, K.; Knoeller, G.; Strutynski, K.; Manser, K.; Dimmock, J.A. (oral presentation) Hepatitis C treatment progress by methadone maintenance patients: Preliminary analysis of a trial of co-located treatment. College on the Problems of Drug Dependence, Quebec City, June 2007
Batki, S.L., Canfield, K.M., Smyth, E., Amodio, K., Manser, K., Levine, R.A. (poster presentation) Effects of medical and psychiatric comorbidity on HCV treatment eligibility in methadone maintenance. College on the Problems of Drug Dependence, Annual Meeting, San Juan, Puerto Rico June, 2008
Cornell, M.E., Peek, R.M.H., Batki, S.L. (2002) Hepatitis C in an Upstate New York methadone treatment population: Preliminary analysis. Drug and Alcohol Dependence 66:S36-37.
Batki, S.L., Srinath, A.K., Cornell, M.E., Bowman, M., Peek, R.M.H., Wade, M., Dimmock, J., Abdul-Hamid, M. (2005) Depression and Substance Use in Methadone Patients with Hepatitis C. American Journal on Addictions 14:304-5.

Responsible Party: Steven Batki, M.D., Prinicpal Investigator, State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier: NCT00148031     History of Changes
Other Study ID Numbers: SUNY UMU IRB # 4929, R01 DA016764
Study First Received: September 2, 2005
Last Updated: April 23, 2013
Health Authority: United States: Federal Government

Keywords provided by State University of New York - Upstate Medical University:
behavior modification
health care service utilization
hepatitis C,
injection drug use
therapy compliance
alcoholism
alcohol abuse
prevention
drug abuse
liver disorder
HCV
methadone

Additional relevant MeSH terms:
Alcoholism
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Alcohol-Related Disorders
Chemically-Induced Disorders
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Mental Disorders
Picornaviridae Infections
RNA Virus Infections
Substance-Related Disorders
Virus Diseases
Interferons
Ribavirin
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 30, 2014